HomeCompareVGREF vs ABBV

VGREF vs ABBV: Dividend Comparison 2026

VGREF yields 692.28% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VGREF wins by $829123.31M in total portfolio value
10 years
VGREF
VGREF
● Live price
692.28%
Share price
$0.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$829123.41M
Annual income
$645,656,795,042.41
Full VGREF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — VGREF vs ABBV

📍 VGREF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVGREFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VGREF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VGREF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VGREF
Annual income on $10K today (after 15% tax)
$58,843.89/yr
After 10yr DRIP, annual income (after tax)
$548,808,275,786.05/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, VGREF beats the other by $548,808,253,919.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VGREF + ABBV for your $10,000?

VGREF: 50%ABBV: 50%
100% ABBV50/50100% VGREF
Portfolio after 10yr
$414561.76M
Annual income
$322,828,410,384.06/yr
Blended yield
77.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VGREF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VGREF buys
0
ABBV buys
0
No recent congressional trades found for VGREF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVGREFABBV
Forward yield692.28%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$829123.41M$104.7K
Annual income after 10y$645,656,795,042.41$25,725.73
Total dividends collected$814237.51M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VGREF vs ABBV ($10,000, DRIP)

YearVGREF PortfolioVGREF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$79,928$69,228.11$11,559$438.51+$68.4KVGREF
2$602,651$517,128.18$13,494$640.86+$589.2KVGREF
3$4,288,859$3,644,021.75$15,951$945.97+$4.27MVGREF
4$28,825,743$24,236,664.30$19,152$1,413.89+$28.81MVGREF
5$183,083,222$152,239,676.79$23,443$2,146.38+$183.06MVGREF
6$1,099,573,723$903,674,675.23$29,391$3,321.96+$1099.54MVGREF
7$6,248,834,638$5,072,290,754.82$37,948$5,265.87+$6248.80MVGREF
8$33,626,094,931$26,939,841,868.20$50,795$8,596.74+$33626.04MVGREF
9$171,464,126,496$135,484,204,920.01$71,034$14,549.41+$171464.06MVGREF
10$829,123,410,393$645,656,795,042.41$104,715$25,725.73+$829123.31MVGREF

VGREF vs ABBV: Complete Analysis 2026

VGREFStock

VIASPACE Green Energy Inc., a renewable energy company, manufacture and sells framed artwork in the United States. It operates through two segments, Framed-Artwork and Grass. The Framed-Artwork segment manufactures copyrighted framed artwork in the People's Republic of China for retail stores. The Grass Segment produces Giant King Grass, a natural hybrid, non-genetically modified, and perennial grass, which is used to generate low carbon and renewable electricity by burning in a biomass power plant; used to produce bio methane through anaerobic digestion; used as a feedstock for non-food liquid biofuels, such as bio ethanol and bio butanol; and used as a feedstock for biochemicals and bio plastics, as well as used as animal feed. The company was founded in 2008 and is headquartered in Marietta, Georgia.

Full VGREF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VGREF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VGREF vs SCHDVGREF vs JEPIVGREF vs OVGREF vs KOVGREF vs MAINVGREF vs JNJVGREF vs MRKVGREF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.